Pfizer pins post 2028 return to growth on new obesity and cancer drugs

By Mariam Sunny and Christy Santhosh

May 5 (Reuters) - Pfizer said connected Tuesday that it expects to instrumentality to stronger maturation aft 2028, driven by obesity drugs successful development, a patent hold for its bosom cause Vyndamax and a favorable European tribunal ruling ‌on its COVID-19 vaccine.

The New York-based drugmaker besides bushed Wall Street expectations for first-quarter gross and profit, buoyed by beardown request for its ‌blood thinner Eliquis and precocious acquired products, arsenic it faces looming patent expirations and fading COVID merchandise income amid tighter U.S. vaccine recommendations.

While determination are respective drugs successful the company's pipeline "that ​could marque the communicative much absorbing implicit time," investors volition request to spot much objective information and reduced hazard astir those programs earlier sentiment improves, J.P.Morgan expert Chris Schott said.

OBESITY PUSH

Pfizer's archetypal obesity cause from its $10 cardinal acquisition of Metsera, if palmy successful trials, would not scope the marketplace earlier 2028.

"We person unsocial capabilities arsenic a institution to triumph successful this country some successful presumption of our quality to activate consumers and patients successful precise antithetic ways," Chief U.S. Commercial ‌Officer Aamir Malik said of the obesity marketplace immoderate ⁠analysts spot exceeding $100 cardinal a twelvemonth successful the adjacent decade.

He noted that Pfizer income teams already woody with astir 60% of the physicians who are apt to constitute obesity-drug prescriptions.

CEO Albert Bourla said Pfizer was amazed by "how large the ⁠international marketplace is" aft seeing weight-loss marketplace person Eli Lilly's quarterly study past week.

Lilly reported income of its GLP-1 obesity and diabetes products that acold exceeded Wall Street expectations, driven by higher volumes crossed markets, including overseas.

Pfizer expects to pat maturation successful emerging markets specified arsenic Brazil and Mexico, wherever it has a beardown primary-care presence.

Pfizer's ​first-quarter ​results saw a boost from caller and acquired medicines, including crab cause Padcev and ​migraine attraction Nurtec ODT.

Citi expert Geoff Meacham said the 22% ‌growth successful recently launched and acquired products demonstrates "the commercialized portfolio's quality to offset ongoing COVID franchise declines."

Total income of $14.45 cardinal for the archetypal 4th topped estimates of $13.79 billion.

The institution settled patent disputes with 3 generic drugmakers implicit Vyndamax past week, efficaciously delaying cheaper copies from entering the marketplace done mid-2031.

Bourla said the settlements person the imaginable to alteration the maturation illustration of the institution importantly aft 2028, giving it assurance it volition execute a high-single-digit compounded yearly maturation complaint for a five-year play opening successful 2029.